NCT04900818 2026-03-05Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid TumorsI-Mab Biopharma US LimitedPhase 1 Recruiting330 enrolled
NCT03228667 2026-01-14QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint InhibitorsImmunityBio, Inc.Phase 2 Active not recruiting40 enrolled
NCT02572687 2021-01-20A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic MalignanciesEli Lilly and CompanyPhase 1 Completed85 enrolled
NCT02658214 2020-08-20Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid TumorsAstraZenecaPhase 1 Completed32 enrolled
NCT03544723 2020-06-09Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.MultiVir, Inc.Phase 2 Unknown40 enrolled